Find an expert
Our panel of editors are available for interview
Professor Gisli Jenkins
Chair of the Editorial Board for BMJ Open Respiratory Research
Professor Gisli Jenkins is an NIHR Research Professor and holds the Margaret Turner-Warwick Chair of Thoracic Medicine at Imperial College London, Head of the Margaret Turner-Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute. Prof Jenkins’ research focuses on Interstitial Lung Diseases, and Pulmonary Fibrosis in particular. He is the Principal Investigator of a number of longitudinal observational studies including the PROFILE study, the INJUSTIS Study, the UKILD Post COVID ILD study as well as the DEMISTIFI Multi-Morbidity consortium.
Dr Andrea Cipriani
Editor-in-Chief of Evidence-Based Mental Health
Andrea Cipriani, MD, PhD, is Professor of Psychiatry and NIHR Research Professor at the University of Oxford. He is an honorary consultant psychiatrist at the Associate Director for Oxford Health NHS Foundation Trust in Oxford. His main research interests are evidence-based mental health and precision psychiatry. His research focuses on the evaluation of pharmacological, psychological and psychosocial interventions.
Professor Juan Víctor Ariel Franco
Editor-in-Chief of BMJ Evidence-Based Medicine
Professor Juan Franco is a family doctor at the Hospital Italiano de Buenos Aires, Argentina, and Vice-chair of the Research Department at the Instituto Universitario Hispital Italiano (IUHI), where he is also Director of the Cochrane Associate Centre. He is a professor at IUHI and Universidad Nacional de La Matanza, and editor for the Cochrane Urology Group and a member of Cochrane’s Governing Board.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
